Pharmaceutical combination comprising an anti-cd205 antibody and an immune checkpoint inhibitor
OwnerChristian ROHLFFinventor
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods for increasing the anti-tumor immune response in a patient suffering from cancer, a method for the treatment or prophylaxis of cancer, and a method for enhancing the effectiveness of an inhibitor of PD1/PD-L1 interactions. Also provided are pharmaceutical combinations comprising (a) antibodies, or antigen-binding portions thereof, directed against CD205, and (b) a PD1/PD-L1 checkpoint inhibitor.
Claims190
A method for the treatment or prophylaxis of cancer comprising administering to a patient in need thereof a therapeutically effective amount of an antibody or an antigen binding fragment thereof that modulates the population of CD205+ immune modulatory cells and a therapeutically effective amount of a composition comprising a checkpoint modulator.
A method for enhancing the effectiveness of an inhibitor of PD-1/PD-L1 in a patient identified as being in need thereof, said method comprising administering to said patient (a) a therapeutically effective amount of an antibody or an antigen binding fragment thereof that modulates the population of CD205+ immune modulatory cells and (b) a composition comprising an inhibitor of PD-1/PD-L1 interactions.
A method for increasing the anti-tumor immune response in a patient suffering from cancer comprising administering to said patient a therapeutically effective amount of an antibody or an antigen binding fragment thereof that modulates the population of CD205+ immune modulatory cells.
A method for increasing the number of T-cells in a patient suffering from cancer comprising administering to said patient a therapeutically effective amount of an antibody or an antigen binding fragment thereof which modulates the population of CD205+ immune modulatory cells.
A method for reducing size of a tumor in a patient suffering from cancer comprising administering to said patient a therapeutically effective amount of an antibody or an antigen binding fragment thereof which modulates the population of CD205+ immune modulatory cells.
The method according to any preceding claim wherein, at least 20%, least 30%, least 40%, least 50%, least 60%, least 70%, least 80%, or more, of the CD8+ cells in a blood sample previously isolated from said patient are CD205+.
The method according to any preceding claim wherein, at least 20%, least 30%, least 40%, least 50%, least 60%, least 70%, least 80%, or more, of the CD4+ cells in a blood sample previously isolated from said patient are CD205+.
The method according to any preceding claim wherein, at least 20%, least 30%, least 40%, least 50%, least 60%, least 70%, least 80%, or more, of the pDCs and/or mDCs in a blood sample previously isolated from said patient are CD205+.
The method according to any preceding claim, wherein the antibody or antigen binding portion thereof binds to CD205.
The method according to any preceding claim, wherein the antibody or antigen binding portion thereof binds to CD205 and comprises:
- a heavy chain variable region comprising:
- iii) a first vhCDR comprising SEQ ID NO:
- 5;
- ii) a second vhCDR comprising SEQ ID NO:
- 6;
- iii) a third vhCDR comprising SEQ ID NO:
- 7;
- and
- a light chain variable region comprising:
- iii) a first vlCDR comprising SEQ ID NO:
- 8;
- ii) a second vlCDR comprising SEQ ID NO:
- 9;
- iii) a third vlCDR comprising SEQ ID NO:
- 10;
- wherein optionally any one or more of the above SEQ ID Nos independently comprise one or two amino acid substitutions, preferably conservative substitutions.
The method according to any preceding claim, wherein the antibody or an antigen-binding portion thereof comprises a heavy chain variable region having at least 80%, 85%, 90%, 95% or 99% amino acid sequence identity to SEQ ID NO:
- 1 and a light chain variable region having at least 80%, 85%, 90%, 95% or 99% amino acid sequence identity to SEQ ID NO:
- 2.
The method according to any preceding claim, wherein the antibody which binds to CD205 comprises
- (iii) a heavy chain having at least 80%, 85%, 90%, 95%, 99% or 100% amino acid sequence identity to SEQ ID NO:
- 100;
- and
- (ii) a light chain having at least 80%, 85%, 90%, 95%, 99% or 100% amino acid sequence identity to SEQ ID NO:
- 101.
The method according to any preceding claim, wherein the antibody or an antigen-binding portion thereof further comprises a covalently-attached moiety.
The method according to any preceding claim, wherein said cancer is a CD205 positive cancer.
The method according to any preceding claim, wherein said cancer is selected from the group consisting of gastric cancer, endometrial cancer, esophageal cancer, lung cancer, ovarian cancer, gastroesophageal junction cancer, pancreatic cancer, breast cancer, colorectal cancer, skin cancer, thyroid cancer, kidney cancer, liver cancer, head and neck cancer, bladder cancer, leukaemia, preferably acute myeloid leukaemia or chronic lymphocytic leukaemia, myeloma, preferably multiple myeloma and lymphoma, preferably diffuse large B-cell lymphoma (DLBCL), B-Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT), T-Cell/Histiocyte-Rich B-Cell Lymphoma, Burkitt's Lymphoma, Lymphoplasmacytic Lymphoma, Small Lymphocytic Lymphoma, Marginal Zone Lymphoma, T Cell Lymphoma, Peripheral T-Cell Lymphoma, Anaplastic Large Cell Lymphoma and AngioImmunoblastic T-Cell Lymphoma.
The method according to any preceding claim, wherein the patient is a human.
A pharmaceutical combination comprising:
- iii) an anti CD205 antibody or antigen binding portion thereof, said antibody comprising:
- a heavy chain variable region comprising:
- iii) a first vhCDR comprising SEQ ID NO:
- 5;
- ii) a second vhCDR comprising SEQ ID NO:
- 6;
- iii) a third vhCDR comprising SEQ ID NO:
- 7;
- and
- a light chain variable region comprising:
- iii) a first vlCDR comprising SEQ ID NO:
- 8;
- ii) a second vlCDR comprising SEQ ID NO:
- 9;
- iii) a third vlCDR comprising SEQ ID NO:
- 10;
- and
- b) a checkpoint modulator.
An antibody or antigen binding portion thereof that modulates the population of CD205+ immune modulatory cells for use in increasing the anti-tumor immune response in a patient suffering from cancer.
An antibody or antigen binding portion thereof that modulates the population of CD205+ immune modulatory cells for use in increasing the number of T-cells in a patient suffering from cancer.
A pharmaceutical combination for use in the treatment or prophylaxis of cancer, said combination comprising;
- an antibody or antigen binding portion thereof that modulates the population of CD205+ immune modulatory cells;
- and a composition comprising a checkpoint modulator.
A pharmaceutical combination for use in enhancing the effectiveness of an inhibitor of PD-1/PD-L1 interactions in a patient, said combination comprising;
- an antibody or antigen binding portion thereof that modulates the population of CD205+ immune modulatory cells;
- and a composition comprising an inhibitor of PD1/PD-L1 interactions.
A method for selecting a patient suitable for therapy with an antibody or antigen binding fragment thereof which binds to CD205, wherein said patient is suffering from cancer, said method comprising:
- identifying a patient wherein at least 20% of the CD8+ cells in a blood sample previously isolated from said patient are CD205+ and administering a therapeutically effective amount of an anti CD205 antibody or antigen binding fragment thereof to said patient.
An in vitro method for selecting a patient suitable for treatment with an antibody or antigen binding fragment thereof which binds to CD205 comprising:
- a. determining the percentage of CD8+ cells in a blood sample previously isolated from said patient that are CD205+ cells;
- and
- b. selecting the patient for treatment with the antibody or antigen binding fragment thereof which binds to CD205 if at least 20% of the CD8+ cells in the blood sample CD205+.
A method for determining the efficacy of an antibody or antigen binding fragment thereof which binds to CD205 in the treatment of cancer in a patient, said method comprising
- a. obtaining a blood sample from said patient,
- b. identifying whether at least 20% of the CD8+ cells in the blood sample are CD205+.
A method for selecting a patient suitable for therapy with an antibody or antigen binding fragment thereof which binds to CD205, wherein said patient is suffering from cancer, said method comprising:
- identifying a patient wherein at least 20% of the CD4+ cells in a blood sample previously isolated from said patient are CD205+ and administering a therapeutically effective amount of an anti CD205 antibody or antigen binding fragment thereof to said patient.
An in vitro method for selecting a patient suitable for treatment with an antibody or antigen binding fragment thereof which binds to CD205 comprising:
- a. determining the percentage of CD4+ cells in a blood sample previously isolated from said patient that are CD205+ cells;
- and
- b. selecting the patient for treatment with the antibody or antigen binding fragment thereof which binds to CD205 if at least 20% of the CD4+ cells in the blood sample CD205+.
A method for determining the efficacy of an antibody or antigen binding fragment thereof which binds to CD205 in the treatment of cancer in a patient, said method comprising
- a. obtaining a blood sample from said patient,
- b. identifying whether at least 20% of the CD4+ cells in the blood sample are CD205+.
A method for selecting a patient suitable for therapy with an antibody or antigen binding fragment thereof which binds to CD205, wherein said patient is suffering from cancer, said method comprising:
- identifying a patient wherein at least 20% of the CD8+ and CD4+ cells in a blood sample previously isolated from said patient are CD205+ and administering to said patient a therapeutically effective amount of an anti CD205 antibody or antigen binding fragment thereof to said patient.
An in vitro method for selecting a patient suitable for treatment with an antibody or antigen binding fragment thereof which binds to CD205 comprising:
- a. determining the percentage of CD8+ and CD4+ cells in a blood sample previously isolated from said patient that are CD205+ cells;
- and
- b. selecting the patient for treatment with the antibody or antigen binding fragment thereof which binds to CD205 if at least 20% of the CD8+ and CD4+ cells in the blood sample CD205+.
A method for determining the efficacy of an antibody or antigen binding fragment thereof which binds to CD205 in the treatment of cancer in a patient, said method comprising
- a. obtaining a blood sample from said patient,
- b. identifying whether at least 20% of the CD8+ and CD4+ cells in the blood sample are CD205+.
A method for the treatment or prophylaxis of cancer comprising, identifying a patient wherein at least 20% of the CD8+ cells in a blood sample previously isolated from said patient are CD205+ and administering to said patient a therapeutically effective amount of an antibody or antigen binding fragment thereof which binds to CD205.
A method for the treatment or prophylaxis of cancer comprising, identifying a patient wherein at least 20% of the CD4+ cells in a blood sample previously isolated from said patient are CD205+ and administering to said patient a therapeutically effective amount of an antibody or antigen binding fragment thereof which binds to CD205.
A method for the treatment or prophylaxis of cancer comprising identifying a patient wherein at least 20% of the CD8+ cells and CD4+ cells in a blood sample previously isolated from said patient are CD205+ and administering to said patient a therapeutically effective amount of an antibody or antigen binding fragment thereof which binds to CD205.
A treatment method comprising:
- (a) calculating the percentage of CD4+ and/or CD8+ cells that are CD205+ in a blood sample previously isolated from a patient diagnosed with cancer to identify the patient as having a responder phenotype;
- and
- (b) administering a therapeutically effective amount of an antibody or antigen binding fragment thereof which binds to CD205 to the patient having a responder phenotype.
Dependencies are inferred from the claim text.